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SUMMARY
Introduction/Objective Given the contradictory results regarding the association of liver function 
biomarkers [e.g., alanine-aminotransferase (ALT), gamma-glutamyl transferase (GGT) and total biliru-
bin)] and the risk of cardiovascular disease (CVD), we aimed to explore the relationship between these 
biomarkers and Framingham risk score (FRS), an established tool used in the prediction of 10-year CVD 
risk in the cohort of women.
Methods A total of 278 women participated in this cross-sectional study. Anthropometric, biochemical 
parameters, and blood pressure were obtained.
Results There was a significant increase in ALT and GGT activity, as well as a decrease in total bilirubin 
level in the high-risk FRS group compared to moderate-, and low-risk FRS (p for trend = 0.025, p < 0.001, 
p < 0.001, respectively). Multivariate logistic regression analysis showed that body mass index, triglycer-
ides, creatinine, and high sensitivity C-reactive protein levels were the independent predictors of FRS in 
women [odds ratio (OR) = 1.234, p = 0.001; OR = 2.856, p = 0.001; OR = 1.090, p = 0.002, and OR = 1.295, 
p = 0.045, respectively]. In contrast, total bilirubin, ALT and GGT lost their independent predictions for 
high CVD risk.
Conclusion Liver function biomarkers (i.e. ALT, GGT, and total bilirubin) are not independently associ-
ated with FRS. It seems that some other cardiometabolic disturbances might modulate this relationship.
Keywords: cardiovascular risk; inflammation; obesity; liver function
DOI: https://doi.org/10.2298/SARH181120006K
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INTRODUCTION
Cardiovascular disease (CVD) in women is 
still the leading cause of death in most devel-
oped and developing countries. In addition, the 
manifestation of heart disease differs between 
sexes, often leading to worse consequences in 
women than in men [1]. Women at menopause 
experience increased visceral obesity, insulin 
resistance, and unfavorable hormonal milieu 
compared with women in premenopausal pe-
riod, which leads to increased CVD risk [2]. 
On the other hand, women of reproductive age 
with hypertensive disorders of pregnancy are 
among the populations with the highest risk 
for premature CVD [1].
So far, a larger number of researches deal-
ing with this pathology has been conducted 
in men, but implies the need for the optimal 
screening of women at high CVD risk [1].
Considering a complex phenotype of CVD, 
a search for a variety of biomarkers that act via 
different biological pathways, thus preceding 
overt CVD, has been increased [2, 3]. Among 
them, liver function biomarkers have shown to 
be independently associated with CVD risk in 
many studies so far [4, 5]. In addition, the as-
sociation between severity of ultrasonographic 
nonalcoholic fatty liver disease (NAFLD), as the 
commonest manifestation of hepatic disorder, 
and cardiometabolic risk has been reported [6].
However, research papers lack consistency, 
showing contradictory results on the utility 
of liver function biomarkers when predicting 
CVD risk [7–11]. There are also inconsisten-
cies when sex influence on this relationship is 
concerned, as well as assumptions that associa-
tion of liver function biomarkers with CVD risk 
was dependent on some other potential predic-
tors’ influence [12]. In line with this, although 
concordant results show that aspartate amino-
transferase (AST) was not associated with an 
increased risk for CVD [13], it is still a matter 
of debate whether other liver function bio-
markers [i.e. alanine aminotransferase (ALT), 
gamma glutamyl transferase (GGT), and total 
bilirubin] have a causal role in the pathogen-
esis of CVD or they are just simple markers of 
coexisting CVD risk factors [7–11].
Although the relationship between NAFLD 
and cardiometabolic risk has been shown by 
some previous reports, the underlying patho-
physiological mechanism of this association 
has not yet been clarified [6]. We speculate that 
obesity-related inflammation and dyslipidemia 
might modulate the relationship between liver 
enzymes and CVD risk, having in mind that 
the highest prevalence of NAFLD is observed 
in individuals with obesity or type 2 diabetes 
mellitus (DM2), who have a two-fold risk in-
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Given the contradictory results regarding the relation-
ship of liver function biomarkers (i.e. ALT, GGT, and total 
bilirubin) and risk for CVD, we aimed to explore the rela-
tionship between these biomarkers and Framingham risk 
score (FRS), an established tool used in the prediction of 
10-year CVD risk, in the cohort of women population [12].
METHODS
Study population
The examined cohort included 278 women who volun-
teered to participate in this cross-sectional study. All par-
ticipants were consecutively recruited into the study when 
visiting the Primary Health Care Center in Podgorica, 
Montenegro, for their regular check-up, between October 
2012 and May 2016. Women were regarded to be post-
menopausal if they self-reported the absence of menstrual 
bleeding for more than one year. Examined women were 
considered to have DM2 based on previously described 
criteria [14, 16].
Exclusion criteria for all the women were the following: 
previously known CVD, type 1 diabetes mellitus, preg-
nancy, kidney diseases other than nephropathy, liver dis-
eases other than hepatic steatosis, ethanol consumption > 
20 g/day, gout, high sensitivity C-reactive protein (hsCRP) 
> 10 mg/L, malignant diseases, as well as unwillingness to 
participate in the research.
A total of 70.1% women were overweight/obese, whereas 
32.4% were with DM2. Also, the majority of women (82%) 
were postmenopausal. A total of 14% of women used hy-
polipidemic drugs, whereas 26.3% were treated for hyper-
tension. A total of 29.1% of the patients used oral hypo-
glycemic drugs, and 3.2% of them were on insulin therapy. 
Written informed consent was obtained from all the 
patients. The research was carried out in compliance with 
the Declaration of Helsinki, while the study protocol was 
approved by the Ethical Committee of the Primary Health 
Care Center in Podgorica, Montenegro. 
Anthropometric measurements
All the participants’ anthropometric measurements’ pro-
ceedings have been described previously [15].
Biochemical analyses
Biochemical parameters [i.e. hsCRP, creatinine, glucose, 
total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-c), low-density lipoprotein cholesterol (LDL-c), tri-
glycerides (TG), uric acid, bilirubin, AST, ALT, and GGT], 
were measured as described previously [14, 16]. 
Blood pressure was measured and glomerular filtra-
tion rate was estimated (eGFR), as was shown previously 
[15, 16].
The FRS calculation included information on age, sex, 
TC, HDL-c, smoking status, presence of diabetes, and 
systolic blood pressure (SBP). Thereafter, the cohort of 
studied women was divided into low-risk (FRS < 10%), 
moderate-risk (10% ≤ FRS < 20%), and high-risk FRS sta-
tus (FRS ≥ 20%) [17].
Statistical analyses
Distribution of data was tested with Kolmogorov–Smirnov 
test. Comparisons of continuous normal and log-normal 
variables were performed by ANOVA with the Tukey–
Kramer post hoc test for subgroup differences. Skewed dis-
tributed data were compared by Kruskal–Wallis post hoc 
test. The data are shown as mean ± standard deviation (SD) 
for normally distributed data, geometrical mean [95% con-
fidence interval (CI)] for log-normal distributed data [18], 
median (25th–75th percentile) for skewed distributed data, 
and as relative frequencies for categorical variables. Analysis 
of categorical variables was performed by using the χ2 test 
for contingency tables. Categorical variables were coded 
as follows: smoking status (0 – non-smoker, 1 – smoker); 
diabetes mellitus (0 – without diabetes mellitus, 1 – pa-
tients with diagnosed diabetes mellitus), menopausal status 
(0 – premenopausal, 1 – postmenopausal) and therapy (0 
– no therapy, 1 – therapy). To estimate the correlation be-
tween the examined cardiometabolic parameters with FRS, 
Spearman’s correlation analysis was performed. The data 
were given as correlation coefficient (ρ). Independent asso-
ciations between high FRS and cardiometabolic parameters 
were tested by univariate and multivariate binary logistic 
regression analyses. The low FRS category was coded as 
0, while the medium and high FRS categories were coded 
as 1. To examine independent predictions of continuous 
variables, multivariate adjustment was made for all con-
tinuous variables which did not enter the FRS calculation, 
and which significantly correlated with FRS (p < 0.05), as 
well as categorical variables which were not included in the 
FRS calculation, and which showed unequal distribution 
between low-, moderate-, and high-risk FRS groups. Odds 
ratio (OR) and the 95 CI were estimated. The explained 
variation in FRS was given by Nagelkerke R2 value. The 
Hosmer–Lemeshow test was used to examine if there was 
a linear relationship between the predictor variables and 
the log odds of the dependent variable. Receiver operating 
characteristic (ROC) curve analysis was used to examine 
diagnostic performance of each cardiometabolic param-
eter and the model, as well as to discriminate women with 
moderate and high FRS from those with low FRS. The area 
under the ROC curve (AUC) of 0.5–0.7 suggested that diag-
nostic test had low accuracy; 0.7–0.8 satisfactory accuracy, 
0.8–0.9 good accuracy, while AUC higher than 0.9 sug-
gested excellent accuracy of the diagnostic test [19]. A p-
value less than 0.05 was considered statistically significant. 
All statistical calculations were performed in the PASW® 
Statistics, Version 18 (SPSS Inc., Chicago, IL, USA).
RESULTS
Table 1 summarizes general characteristics of the study 
groups according to their calculated FRS. Women in the 
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high-risk FRS group were older and had higher body 
mass index (BMI) than those in low-and moderate-risk 
FRS groups. Also, women in the moderate-risk FRS group 
were older and had higher BMI than women in the low-risk 
group. SBP and DBP were significantly lower in the low-risk 
FRS group than in the moderate- and high-risk group. As 
expected, the high-risk FRS group had significantly higher 
percentage of smokers, women with DM2, women on hypo-
lipidemic, antihypertensive, oral hypoglycemic and insulin 
therapies, compared to low- and moderate-risk FRS groups. 
Higher percentage of postmenopausal women were in the 
moderate- and high- FRS group than in the low-risk one. 
Although TC was entered into the FRS calculation 
algorithm, its concentration was not significantly differ-
ent between low-, moderate-, and high-risk FRS group of 
women (Table 2). The HDL-c concentration was higher 
in the first than in the second and third risk group. Also, 
its concentration was higher in the moderate- than in the 
high-risk FRS group. The opposite was found for glucose 
concentration in women. Moreover, TG, creatinine, uric 
acid, and hsCRP concentrations were higher in the mod-
erate- and high-risk FRS groups than in the first one. The 
lowest bilirubin concentrations were determined in the 
high-risk FRS group. ALT activities were higher in the 
moderate- than in the low-risk FRS group, whereas GGT 
activities were the highest in the high-risk FRS group. 
Beside parameters used in its algorithm, FRS signifi-
cantly positively correlated with BMI, DBP, TG, glucose, 
creatinine, uric acid, hsCRP, ALT, and GGT. Significant 
negative correlations were established between FRS and 
HDL-c, which was used for its calculation, and between 
FRS and total bilirubin (Table 3).
Table 1. General characteristics of the studied patients
Characteristics Low risk(FRS < 10%)
Moderate risk
(10% ≤ FRS < 20%)
High risk
(FRS ≥ 20%) p
n 144 65 69
Age, years 53 (48–57) 61 (55–64)a* 66 (61–70)a*, b* < 0.001
BMI, kg/m2 25.5 (22.7–28.3) 28.3 (26.2–33.3)a* 31.2 (28.7–33.9)a*, b* < 0.001
SBP, mmHg 125 (110–135) 150 (130–158)a* 140 (130–155)a* < 0.001
DBP, mmHg 76 (68–86) 90 (80–97)a* 80 (75–90)a* < 0.001
Smokers, % 8.33 3.08 17.40 0.015
Diabetes mellitus, % 4.86 35.38 87 < 0.001
Menopausal status, % 69.44 95.38 95.65 < 0.001
Hypolipidemics, % 0.69 13.85 42.03 < 0.001
Antihypertensives, % 2.78 26.15 75.36 < 0.001
Oral antidiabetics, % 4.17 29.23 81.16 < 0.001
Insulin therapy, % 0.69 4.62 7.25 0.032
Data are presented as median (interquartile range) and compared by Kruskal–Wallis test; categorical variables are presented as relative frequencies and com-
pared by χ2 test; 
BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; FRS – Framingham risk score; 
asignificantly different from the first group; post-hoc Kruskal–Wallis test; 
bsignificantly different from the second group; post-hoc Kruskal–Wallis test; 
*p < 0.05
Table 2. Clinical parameters of women in different Framingham risk score groups





TC, mmol/L 5.97 ± 1.16 6.34 ± 1.11 5.93 ± 1.26 0.125
HDL-c, mmol/L 1.71 ± 0.43 1.46 ± 0.33a* 1.25 ± 0.29a*, b* < 0.001
LDL-c, mmol/L 3.77 ± 1.09 4.19 ± 1.12 3.72 ± 1.21 0.052
TG, mmol/L+ 1.18 (1.11–1.27) 1.76 (1.59–1.95)a* 2 (1.78–2.23)a* < 0.001
Glucose, mmol/L++ 5.2 (4.9–5.6) 6.0 (5.2–7.2)c* 7.0(6.2–8.1)c*, d* < 0.001
Creatinine, µmol/L++ 57 (51–62) 59 (54–65)c* 64 (57–74)c* < 0.001
Uric acid, µmol/L+ 235 (226–245) 277 (254–302)a* 300 (282–320)a* < 0.001
Total bilirubin, µmol/L++ 7.20 (5.80–9.32) 7.10 (5.20–9.85) 5.70 (4.17–7.12)c*, d < 0.001
HsCRP, mg/L+ 0.87 (0.74–1.02) 1.62 (1.23–2.14)a* 2.33 (1.88–2.89)a* < 0.001
AST, U/L++ 18 (15–21) 18 (16–22) 18 (16–22) 0.352
ALT, U/L++ 17 (13–22) 21 (14–27)c* 19 (15–27) 0.025
GGT, U/L++ 11 (9–16) 14 (10–16) 17 (14–25)c*, d* < 0.001
Data are presented as arithmetic mean ± SD and compared with Student’s t-test; 
TC – total cholesterol; HDL-c – high density lipoprotein cholesterol; LDL-c – low density lipoprotein cholesterol; TG – triglycerides; hsCRP – high-sensitivity C-
reactive protein; AST – aspartate aminotransferase; ALT – alanine aminotransferase; GGT – gamma-glutamyl transferase; FRS – Framingham risk score; 
+log-normal distributed data are presented as geometric mean (95% CI) and compared with Student’s t-test after logarithmic transformation; 
++skewed distributed data are presented as median (interquartile range) and compared with Mann–Whitney U-test; 
asignificantly different from the low risk group; post-hoc Tuckey–Kramer test; 
bsignificantly different from the medium risk group; post-hoc Tuckey–Kramer test; 
csignificantly different from the low risk group; post-hoc Kruskal–Wallis test; 
dsignificantly different from the medium risk group; post-hoc Kruskal–Wallis test; 
*p < 0.05
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Logistic regression analysis was used to test if any of 
cardiometabolic parameters which were not used in FRS 
algorithm and showed significant correlations (p < 0.05) 
with FRS, had potential to predict high CVD risk (Table 
4). Those predictors were continuous variables such as 
BMI, DBP, LDL-c, TG, creatinine, uric acid, total biliru-
bin, hsCRP, ALT, and GGT, as well as categorical variables 
such as menopausal status and hypolipidemic therapy. 
Predictors were unadjusted and adjusted for other param-
eters and tested by univariate and multivariate analysis, 
respectively (Table 4). Significant OR for tested predic-
tors from univariate analysis were shown in Table 4. It was 
shown that BMI, TG, creatinine, total bilirubin, hsCRP, 
ALT, and GGT were significant predictors for higher FRS. 
As BMI rose for 1 kg/m2, TG for 1 mmol/L, creatinine for 
1 μmol/L, hsCRP for 1 mg/L, ALT for 1 U/L, and GGT for 
1 U/L, probability for higher CVD risk rose by 30%, 4.358 
times, 6%, 37.5%, 2.8%, and 2.6%, respectively. As total 
bilirubin concentration rose by 1 μmol/L, probability for 
higher CVD risk decreased by 8.5%. Nagelkerke R2 showed 
that each predictor in univariate analysis, BMI, TG, creati-
nine, total bilirubin, hsCRP, ALT, and GGT could explain 
the variation in higher risk for CVD occurrence by 32.8%, 
27.3%, 12%, 3.6%, 13.2 %, 2.5%, and 3.2%, respectively. All 
predictors tested in univariate analysis (BMI, DBP, LDL-c, 
TG, creatinine, uric acid, total bilirubin, hsCRP, ALT, GGT, 
menopausal status, and hypolipidemic therapy) were fur-
ther tested in multivariate logistic regression analysis in 
order to determine their independent association with high 
FRS. Namely, four parameters having significant odds in 
univariate analysis (BMI, TG, creatinine, and hsCRP) kept 
independent predictive power for high CVD risk in the 
model. In contrast, total bilirubin, ALT, and GGT lost their 
independent predictions for high CVD risk. In multivariate 
analysis, as BMI rose by 1 kg/m2, TG by 1 mmol/L, cre-
atinine by 1 μmol/L, and hsCRP by 1mg/L, probability 
for higher CVD risk rose by 23.4%, 2.856 times, 9%, and 
29.5%, respectively. Nagelkerke R2 of 0.725 showed that 
the model could explain 72.5% of variation in the FRS.
Thereafter, a ROC analysis was used to discriminate 
women with low risk from those with moderate and high 
risk of developing CVD (Table 5). The calculated AUC 
for BMI, TG, and hsCRP indicated satisfactory accuracy, 
whereas ROC analysis showed low accuracy for creatinine, 
total bilirubin, ALT, and GGT as diagnostic tools. The cal-
culated AUC for the model (which included BMI, DBP, 
LDL-c, TG, creatinine, uric acid, total bilirubin, hsCRP, 
ALT, GGT, menopausal status, and hypolipidemic therapy) 
was 0.944, which suggested excellent clinical accuracy. 
Also, the model had higher sensitivity than single predic-
tors (Table 5, Figure 1).
DISCUSSION
The findings of the current study reveal that liver func-
tion biomarkers (i.e. ALT, GGT, and total bilirubin) are 
not independently associated with FRS, even though there 
was a significant increase in ALT and GGT activity, as well 
as a decrease in total bilirubin level in the high-risk FRS 
group compared to the moderate- and low-risk FRS group 
(Table 2). In addition, although all these biomarkers cor-
related with FRS in Spearman’s non-parametric correla-
tion analysis (Table 3), in multivariate logistic regression 
analysis these biomarkers lost their independent predic-
tions for high CVD risk (Table 4). This may give rise to the 
Table 3. Bivariate Spearman’s correlation analysis between Framing-




Age, years 0.703 < 0.001
BMI, kg/m2 0.578 < 0.001
SBP, mmHg 0.606 < 0.001
DBP, mmHg 0.447 < 0.001
TC, mmol/L 0.172 0.004
HDL-c, mmol/L -0.510 < 0.001
LDL-c, mmol/L 0.201 0.001
TG, mmol/L+ 0.559 < 0.001
Glucose, mmol/L++ 0.639 < 0.001
Creatinine, µmol/L++ 0.279 < 0.001
Uric acid, µmol/L+ 0.459 < 0.001
Total bilirubin, µmol/L++ -0.241 < 0.001
HsCRP, mg/L+ 0.435 < 0.001
AST, U/L++ 0.035 0.564
ALT, U/L++ 0.120 < 0.001
GGT, U/L++ 0.407 < 0.001
BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood 
pressure; TC – total cholesterol; HDL-c – high density lipoprotein cholesterol; 
LDL-c – low density lipoprotein cholesterol; TG – triglycerides; hsCRP – high-
sensitivity C-reactive protein; AST – aspartate aminotransferase; ALT – alanine 
aminotransferase; GGT – gamma-glutamyl transferase; FRS – Framingham risk 
score 
+log-normal distributed data are presented as geometric mean (95% CI) and 
compared with Student’s t-test after logarithmic transformation; 
++skewed distributed data are presented as median (interquartile range) and 
compared with Mann–Whitney U-test
Table 4. Odds ratios (OR) after univariate and multivariate logistic re-
gression analysis for parameters predicting Framingham risk score risk
Predictors UnadjustedOR (95% CI) p
Nagelkerke
R2
BMI, kg/m2 1.300 (1.210–1.396) 0.015 0.328
TG, mmol/L 4.358 (2.817–6.743) < 0.001 0.273
Creatinine, µmol/L 1.060 (1.033–1.088) < 0.001 0.120
Total bilirubin, µmol/L 0.915 (0.854–0.980) 0.011 0.036
HsCRP, mg/L 1.375 (1.204–1.571) < 0.001 0.132
ALT, U/L 1.028 (1.003–1.054) 0.021 0.025
GGT, U/L 1.026 (1.004–1.049) 0.021 0.032
Model AdjustedOR (95% CI) p
Nagelkerke
R2




TG, mmol/L 2.856 (1.545–5.277) 0.001
Creatinine, µmol/L 1.090 (1.033–1.150) 0.002
Total bilirubin, µmol/L 0.930 (0.823–1.052) 0.249
HsCRP, mg/L 1.295 (1.085–1.490) 0.045
ALT, U/L 1.008 (0.955–1.063) 0.782
GGT, U/L 1.003 (0.963–1.004) 0.893
Model: BMI, DBP, LDL-c, TG, creatinine, uric acid, total bilirubin, hsCRP, ALT, and 
GGT (all continuous variables); menopausal status and hypolipidemic therapy 
(categorical variable); 
BMI – body mass index; TG – triglycerides; HsCRP – high-sensitivity C-reactive 
protein; ALT – alanine aminotransferase; GGT – gamma-glutamyl transferase
DOI: https://doi.org/10.2298/SARH181120006K
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assumption that these biomarkers might only be bystand-
ers in CVD prediction, instead of direct contributors to 
CVD onset and progression. 
Indeed, previous findings have shown that the association 
of GGT with FRS is dependent on the other potential predic-
tors [12]. Furthermore, the addition of GGT to traditional 
risk factors does not improve CVD risk prediction [8, 20].
Concerning the ALT activity in relation to CVD risk, 
several large sample studies reported that ALT is positively 
associated with CVD events and long-term mortality in 
middle-aged adults, independently of other cardiometa-
bolic factors [21, 22, 23]. However, some others suggest 
that ALT level is not a reliable marker for screening 
for the CVD occurrence in the general population [7], 
whereas some of them found an inverse relationship 
between ALT levels in the normal range and adverse 
cardiovascular and non-cardiovascular outcomes [24].
Similar discordant results were also found for 
bilirubin. While some studies report its independent 
relationship with CVD risk [5, 9], others claim the op-
posite [11]. Moreover, the addition of total bilirubin to 
traditional risk factors showed no significant improve-
ment in prediction of CVD risk [9].
There is also sex difference concerning the relation-
ship between liver enzymes and CVD risk, showing 
that GGT was positively associated only with higher 
levels of FRS in women, but not in men [12]. On the 
other hand, ALT showed a significant inverse relation-
ship with FRS in men, while this relationship remained 
significant in women only for lower and intermediate 
FRS status [12].
We speculate that some other cardiometabolic dis-
turbances (e.g. obesity-related dyslipidemia and in-
flammation) might modulate the relationship between 
liver function biomarkers and CVD risk. In line with 
this, unlike liver function biomarkers (i.e. ALT, GGT, 
and total bilirubin), BMI, TG, hsCRP, and creatinine were 
the independent predictors of FRS in women in our study 
(Table 4), showing that as BMI rose by 1 kg/m2, TG by 
1 mmol/L, creatinine by 1 μmol/L, and hsCRP by 1mg/L, 
probability for higher CVD risk rose by 23.4%, 2.856 times, 
9%, and 29.5%, respectively, suggesting that the mentioned 
model could explain as much as 72.5% of variation in 
the FRS. Moreover, a ROC analysis used to discriminate 
women without low risk from those at moderate and high 
risk for developing CVD, revealed that calculated AUC 
for BMI, TG, and hsCRP indicated satisfactory accuracy, 
whereas ROC analysis showed low accuracy for creatinine, 
total bilirubin, ALT, and GGT as diagnostic tools (Table 5).
One of the potential explanations for such findings may 
lie in the obesity status and its relationship with CVD [25]. 
In our study, a total of 70.1% of examined women were over-
weight/obese. Moreover, the majority of individuals with 
NAFLD are obese [15], which was found to be the inde-
pendent risk factor for progression of this hepatic disorder 
[6]. Namely, in the obese state, an increase in free radicals’ 
production, a decrease in antioxidant defense [14, 26], as 
well as low-grade inflammation with consequent insulin re-
sistance [15, 27], lead to an increased free fatty acids hepatic 
influx. These pathophysiological processes further aggravate 
increased lipogenesis and triglyceride storage, thus promot-
ing dysfunction of hepatocytes [28]. All of these metabolic 
disturbances may lead to increased ALT and GGT activity, 
and to a decreased bilirubin level [6, 25]. Moreover, not only 
do high levels of free fatty acids in addition to insulin resis-
tance lead to hepatocytes dysfunction, but they also promote 
endothelial dysfunction, reduce production of nitric oxide, 
vasoconstriction, and inflammation with consequent initia-
tion and progression of atherosclerosis [29, 30], thus further 
supporting the link between obesity, high triglycerides, and 
inflammation level and CVD.
Table 5. Receiver operating characteristic analysis for single parameters 
and the model discriminatory abilities regarding Framingham risk score 
in the studied patients





BMI, kg/m2 0.800  (0.748–0.845) 0.026 81 66 < 0.001








(0.521–0.654) 0.034 40 76 0.012
HsCRP, mg/L 0.739  (0.684–0.790) 0.029 79 58 < 0.001
ALT, U/L 0.594  (0.528–0.661) 0.034 79 37 0.006
GGT, U/L 0.693  (0.631–0.755) 0.031 63 70 < 0.001
Model 0.944  (0.910–0.968) 0.012 90 83 < 0.001
Model: BMI, DBP, LDL-c, TG, creatinine, uric acid, total bilirubin, hsCRP, ALT and 
GGT (all continuous variables); menopausal status and hypolipidemic therapy 
(categorical variable); 
AUC – area under the ROC curve; BMI – body mass index; TG – triglycerides;  
hsCRP – high-sensitivity C-reactive protein; ALT – alanine aminotransferase;  
GGT-gamma-glutamyl transferase
Figure 1. Discriminatory ability of the model regarding cardiovascular 
disease risk
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The limitations of this study need to be reported. Namely, 
the cross-sectional design of our study does not allow us to 
establish the causal link between liver function biomarkers 
and CVD risk. Also, we have included only women popula-
tion in our study. Thus, longitudinal studies comprising both 
sexes are needed to explore the mechanism of this relation-
ship in order to elucidate if liver function biomarkers have 
a causal role in the pathogenesis of CVD.
CONCLUSION
Liver function biomarkers (i.e. ALT, GGT, and total 
bilirubin) are not independently associated with FRS. It 
seems that some other cardiometabolic disturbances (e.g. 
obesity-related dyslipidemia and inflammation) might 
modulate this relationship. New large sample-size studies 
with longitudinal design and with both sexes included are 
needed to clarify the potential mechanism of the relation-
ship between liver function biomarkers and CVD risk.
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САЖЕТАК
Увод/Циљ С обзиром на контрадикторне резултате који се 
односе на повезаност биомаркера функције јетре [аланин-
аминотрансферазе (АЛТ), гама-глутамил трансферазе (ГГТ) 
и укупног билирубина)] и ризика за појаву кардиоваску-
ларних болести, циљ студије је био да се испита повезаност 
између ових биомаркера и Фрамингхамског скора за ризик 
(ФСР), алгоритма за процену 10-годишњег ризика за појаву 
кардиоваскуларних болести у кохорти женске популације. 
Методе У овој студији пресека учествовало је укупно 278 
жена. Мерени су антропометријски, биохемијски параметри 
и крвни притисак. 
Резултати Уочен је статистички значајан пораст активности 
АЛТ и ГГТ, као и пад вредности укупног билирубина у групи 
са високим статусом ФСР, у поређењу са средњим и ниским 
ФСР (p = 0,025, p < 0,001, p < 0,001, редом). Мултиваријантна 
логистичка регресиона анализа показала је да су индекс 
телесне масе, вредности триглицерида, креатинина и висо-
коосетљивог c-реактивног протеина независни предиктори 
ФСР код жена (OR = 1,234, p = 0,001; OR = 2,856, p = 0,001; 
OR = 1,090, p = 0,002 и OR = 1,295, p = 0,045, редом). С друге 
стране, укупни билирубин, АЛТ и ГГТ су изгубили независну 
предикцију за високи ризик за појаву кардиоваскуларних 
болести.
Закључак Биомаркери функције јетре (тј. АЛТ, ГГТ и укупни 
билирубин) нису независно повезани са ФСР. Претпоставља 
се да неки други кардиометаболички поремећаји могу ути-
цати на ову повезаност.
Кључне речи: ризик за појаву кардиоваскуларних болести; 
инфламација; гојазност; функција јетре
Да ли су биомаркери функције јетре независно повезани са Фрамингхамским 
скором за ризик у женској популацији?
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